Hypertonic Saline in NCFB (NCT06242795)
Effect of Hypertonic Saline on Mucociliary Clearance in Non-CF Bronchiectasis
π©Ί Plain-English Summary (8th-Grade Level)
The purpose of this single arm clinical trial is to evaluate the effects of 7% hypertonic saline (HS) delivered by nebulizer on clearance of mucus from the lungs in people with bronchiectasis (dilated airways) not due to cystic fibrosis. Mucociliary clearance (MCC) to measure the rate at which a person's lungs can clear inhaled particles will be assessed at baseline, and after acute (single dose) HS treatment, as well as after two weeks of treatment with HS. The study has two main questions: 1. Evaluate the repeatability MCC measures in people with non-CF bronchiectasis 2. Compare MCC at baseline (before treatment with HS), after a single dose of HS (acute effect of HS), and after two weeks of treatment with HS twice a day (sustained effect of HS). Participants will participate in up to 5 study visits if completing both Aim 1 and Aim 2: 1 screening/enrollment visit, 2 baseline visits (1 baseline visit if only participating in Aim 2), 1 visit during which first dose of HS would be administered and assessed, and 1 visit after 2 weeks of treatment with HS.
Who can join: Review the eligibility criteria below.
Location: University of North Carolina at Chapel Hill β Chapel Hill, North Carolina
Age range: 18 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (1 Sites)
- University of North Carolina at Chapel Hill β Chapel Hill, North Carolina
π Contact the Study Coordinator
Phone: (919) 966-9198
Email: katherine.despotes@unchealth.unc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Bronchiectasis
- Clairleafα΅α΄Ή: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine β Newport Beach, California
- Simeox 200 US Study β Charleston, South Carolina
- OLE Therapy With BE Patients in Home Care Study β New Haven, Connecticut
- The AIRTIVITYβ’ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis β Birmingham, Alabama
- Itraconazole Therapy In Bronchiectasis With Airway Mold β Rochester, Minnesota
Explore by condition: All Bronchiectasis clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.